These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31685159)

  • 1. Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement.
    Novo M; Ruff MW; Skrabek PJ; Lin Y
    Mayo Clin Proc; 2019 Nov; 94(11):2361-2364. PubMed ID: 31685159
    [No Abstract]   [Full Text] [Related]  

  • 2. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
    Locke FL; Go WY; Neelapu SS
    JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.
    Papadouli I; Mueller-Berghaus J; Beuneu C; Ali S; Hofner B; Petavy F; Tzogani K; Miermont A; Norga K; Kholmanskikh O; Leest T; Schuessler-Lenz M; Salmonson T; Gisselbrecht C; Garcia JL; Pignatti F
    Oncologist; 2020 Oct; 25(10):894-902. PubMed ID: 32339368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.
    Badar T; Johnson BD; Hamadani M
    Bone Marrow Transplant; 2021 Mar; 56(3):683-685. PubMed ID: 32782349
    [No Abstract]   [Full Text] [Related]  

  • 6. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
    Shapiro LC; Mustafa J; Lombardo A; Khatun F; Joseph F; Gillick K; Naik A; Elkind R; Abreu M; Fehn K; de Castro A; Pradhan K; Binakaj D; Nelson R; Paroder M; Uehlinger J; Gritsman K; Alejandro Sica R; Kornblum N; Shastri A; Mantzaris I; Bachier-Rodriguez L; Verma A; Braunschweig I; Goldfinger M
    Bone Marrow Transplant; 2021 Jul; 56(7):1761-1763. PubMed ID: 33846558
    [No Abstract]   [Full Text] [Related]  

  • 8. Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.
    Chow VA; Gopal AK; Gauthier J; Tseng YD; Turtle CJ; Maloney DG; Shadman M
    Blood Adv; 2020 Oct; 4(19):4869-4872. PubMed ID: 33031539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
    Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
    J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):e122-e123. PubMed ID: 30036350
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.
    Spiegel JY; Dahiya S; Jain MD; Tamaresis J; Nastoupil LJ; Jacobs MT; Ghobadi A; Lin Y; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Goy A; Vu K; Andreadis C; Munoz J; Bennani NN; Vose JM; Dorritie KA; Neelapu SS; Locke FL; Rapoport AP; Hill BT; Miklos DB
    Blood; 2021 Apr; 137(13):1832-1835. PubMed ID: 33156925
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.
    Byrne M; Oluwole OO; Savani B; Majhail NS; Hill BT; Locke FL
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):e344-e351. PubMed ID: 31279751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
    Kittai AS; Bond DA; William B; Saad A; Penza S; Efebera Y; Larkin K; Wall SA; Choe HK; Bhatnagar B; Vasu S; Brammer J; Shindiapina P; Long M; Mims A; O'Donnell L; Bhat SA; Rogers KA; Woyach JA; Byrd JC; Jaglowski SM
    Blood Adv; 2020 Oct; 4(19):4648-4652. PubMed ID: 33002129
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.
    Mian A; Wei W; Winter AM; Khouri J; Jagadeesh D; Anwer F; Gerds AT; Dean RM; Sobecks R; Pohlman B; Hamilton BK; Majhail NS; Hill BT
    Leuk Lymphoma; 2021 Jun; 62(6):1344-1352. PubMed ID: 33375873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
    Nair R; Neelapu SS
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma.
    Raychaudhuri R; Qualtieri J; Garfall AL
    Am J Hematol; 2020 Jan; 95(1):E28-E30. PubMed ID: 31725923
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
    Neelapu SS; Jacobson CA; Oluwole OO; Munoz J; Deol A; Miklos DB; Bartlett NL; Braunschweig I; Jiang Y; Kim JJ; Zheng L; Rossi JM; Locke FL
    Blood; 2020 Jun; 135(23):2106-2109. PubMed ID: 32181801
    [No Abstract]   [Full Text] [Related]  

  • 18. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
    Ghafouri S; Timmerman J; Larson S; Mead MD
    Bone Marrow Transplant; 2021 Apr; 56(4):974-977. PubMed ID: 33168933
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
    Bouchkouj N; Kasamon YL; de Claro RA; George B; Lin X; Lee S; Blumenthal GM; Bryan W; McKee AE; Pazdur R
    Clin Cancer Res; 2019 Mar; 25(6):1702-1708. PubMed ID: 30413526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.